Prostaglandin 15d-PGJ2 inhibits androgen receptor signaling in prostate cancer cells

Molecular Endocrinology

Volumn 27, Issue 2, 2013, Pages 212-223

  Kaikkonen, Sanna ^a   Paakinaho, Ville ^a   Sutinen, Päivi ^a   Levonen, Anna Liisa ^a   Palvimo, Jorma J ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ANDROGEN RECEPTOR; FKBP51 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; TMPRSS2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHROMATIN IMMUNOPRECIPITATION; COS CELLS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENES, REPORTER; HUMANS; MALE; PPAR GAMMA; PROSTAGLANDIN D2; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; TACROLIMUS BINDING PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UBIQUITINS;

EID: 84873049372     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1313     Document Type: Article

References (60)

1. Shen MM, Abate-Shen C 2010 Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24:1967-2000
2. Saitoh H, Hinchey J 2000 Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275:6252-6258
3. Heinlein CA, Chang C 2004 Androgen receptor in prostate cancer. Endocr Rev 25:276-308
4. Basu S, Tindall DJ 2010 Androgen action in prostate cancer. Horm Cancer 1:223-228
5. Gao W 2010 Androgen receptor as a therapeutic target. Adv Drug Deliv Rev 62:1277-1284
6. Bonkhoff H, Berges R 2010 From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70:100-112
7. Saraon P, Jarvi K, Diamandis EP 2011 Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 57:1366-1375
8. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP 1995 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406
9. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP 1997 Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319
10. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555
11. Aranda A, Pascual A 2001 Nuclear hormone receptors and gene expression. Physiol Rev 81:1269-1304
12. Gao W, Bohl CE, Dalton JT 2005 Chemistry and structural biology of androgen receptor. Chem Rev 105:3352-3370
13. Heemers HV, Tindall DJ 2007 Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778-808
14. Chen F, Knecht K, Leu C, Rutledge SJ, Scafonas A, Gambone C, Vogel R, Zhang H, Kasparcova V, Bai C, Harada S, Schmidt A, Reszka A, Freedman L 2004 Partial agonist/antagonist properties of androstenedione and 4-androsten-3β, 17β-diol. J Steroid Biochem Mol Biol 91:247-257
15. Gioeli D, Paschal BM 2012 Post-translational modification of the androgen receptor. Mol Cell Endocrinol 352:70-78
16. Anbalagan M, Huderson B, Murphy L, Rowan BG 2012 Posttranslational modifications of nuclear receptors and human disease. Nucl Recept Signal 10:e001
17. Poukka H, Karvonen U, Janne OA, Palvimo JJ 2000 Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97:14145-14150
18. Kaikkonen S, Jääskeläinen T, Karvonen U, Rytinki MM, Makkonen H, Gioeli D, Paschal BM, Palvimo JJ 2009 SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol Endocrinol 23:292-307
19. Kansanen E, Kivelä AM, Levonen AL 2009 Regulation of Nrf2-dependent gene expression by 15-deoxy-Δ12, 14-prostaglandin J2. Free Radic Biol Med 47:1310-1317
20. Hardy KD, Cox BE, Milne GL, Yin H, Roberts 2nd LJ 2011 Nonenzymatic free radical-catalyzed generation of 15-deoxy-Δ(12, 14)-prostaglandin J-like compounds (deoxy-J-isoprostanes) in vivo. J Lipid Res 52:113-124
21. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-Δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812
22. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819
23. Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H 2005 α, β-Unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J Biol Chem 280:14145-14153
24. Cernuda-Morollón E, Pineda-Molina E, Canada FJ, Pérez-Sala D 2001 15-Deoxy-Δ 12, 14-prostaglandin J2 inhibition of NF-κBDNA binding through covalent modification of the p50 subunit. J Biol Chem 276:35530-35536
25. Pérez-Sala D, Cernuda-Morollón E, Cañada FJ 2003 Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Δ12, 14-prostaglandin J2. J Biol Chem 278:51251-51260
26. Kim DH, Kim EH, Na HK, Sun Y, Surh YJ 2010 15-Deoxy-Δ(12, 14)-prostaglandin J(2) stabilizes, but functionally inactivates p53 by binding to the cysteine 277 residue. Oncogene 29:2560-2576
27. Kim HJ, Kim JY, Meng Z, Wang LH, Liu F, Conrads TP, Burke TR, Veenstra TD, Farrar WL 2007 15-Deoxy-Δ12, 14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-α via covalent modification of DNA-binding domain. Cancer Res 67:2595-2602
28. Tempé D, Piechaczyk M, Bossis G 2008 SUMO under stress. Biochem Soc Trans 36:874-878
29. Manza LL, Codreanu SG, Stamer SL, Smith DL, Wells KS, Roberts RL, Liebler DC 2004 Global shifts in protein sumoylation in response to electrophile and oxidative stress. Chem Res Toxicol 17:1706-1715
30. Makkonen H, Kauhanen M, Paakinaho V, Jääskeläinen T, Palvimo JJ 2009 Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res 37:4135-4148
31. Rytinki MM, Kaikkonen S, Sutinen P, Palvimo JJ 2011 Analysis of androgen receptor SUMOylation. Methods Mol Biol 776:183-197
32. Karvonen U, Kallio PJ, Jänne OA, Palvimo JJ 1997 Interaction of androgen receptors with androgen response element in intact cells. Roles of amino-and carboxyl-terminal regions and the ligand. J Biol Chem 272:15973-15979
33. Moilanen A, Rouleau N, Ikonen T, Palvimo JJ, Jänne OA 1997 The presence of a transcription activation function in the hormonebinding domain of androgen receptor is revealed by studies in yeast cells. FEBS Lett 412:355-358
34. Thompson J, Saatcioglu F, Jänne OA, Palvimo JJ 2001 Disrupted amino-and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol 15:923-935
35. Makkonen H, Jääskeläinen T, Pitkänen-Arsiola T, Rytinki M, Waltering KK, Mättö M, Visakorpi T, Palvimo JJ 2008 Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells. Oncogene 27:4865-4876
36. Makkonen H, Kauhanen M, Jääskeläinen T, Palvimo JJ 2011 Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol Cell Endocrinol 331:57-65
37. Rytinki M, Kaikkonen S, Sutinen P, Paakinaho V, Rahkama V, Palvimo JJ 2012 Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol Cell Biol 32:4195-4205
38. Korenchuk S, Lehr JE, McLean L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ 2001 VCaP, a cell-based model system of human prostate cancer. In Vivo 15:163-168
39. Kansanen E, Jyrkkänen HK, Volger OL, Leinonen H, Kivelä AM, Häkkinen SK, Woodcock SR, Schopfer FJ, Horrevoets AJ, Ylä-Herttuala S, Freeman BA, Levonen AL 2009 Nrf2-dependent and-independent responses to nitro-fatty acids in human endothelial cells: identification of heat shock response as the major pathway activated by nitro-oleic acid. J Biol Chem 284:33233-33241
40. Kansanen E, Bonacci G, Schopfer FJ, Kuosmanen SM, Tong KI, Leinonen H, Woodcock SR, Yamamoto M, Carlberg C, Ylä-Herttuala S, Freeman BA, Levonen AL 2011 Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine 151-independent mechanism. J Biol Chem 286:14019-14027
41. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK 2005 A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437:759-763
42. Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, Morrow JD, Darley-Usmar VM 2004 Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 378:373-382
43. Ikonen T, Palvimo JJ, Jänne OA 1997 Interaction between the amino-and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 272:29821-29828
44. Li J, Fu J, Toumazou C, Yoon HG, Wong J 2006 A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol Endocrinol 20:776-785
45. Lands WE 1979 The biosynthesis and metabolism of prostaglandins. Annu Rev Physiol 41:633-652
46. Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K 2002 15-deoxy-Δ 12, 14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem 277:10459-10466
47. Tokugawa Y, Kunishige I, Kubota Y, Shimoya K, Nobunaga T, Kimura T, Saji F, Murata Y, Eguchi N, Oda H, Urade Y, Hayaishi O 1998 Lipocalin-type prostaglandin D synthase in human male reproductive organs and seminal plasma. Biol Reprod 58:600-607
48. Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN, Diamond MI 2005 The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 102:9802-9807
49. Ryan AJ, Chen BB, Vennalaganti PR, Henderson FC, Tephly LA, Carter AB, Mallampalli RK 2008 15-deoxy-Δ12, 14-prostaglandin J2 impairs phosphatidylcholine synthesis and induces nuclear accumulation of thiol-modified cytidylyltransferase. J Biol Chem 283:24628-24640
50. Kar R, Singha PK, Venkatachalam MA, Saikumar P 2009 A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. Oncogene 28:2556-2568
51. Kondo M, Oya-Ito T, Kumagai T, Osawa T, Uchida K 2001 Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem 276:12076-12083
52. Shibata T, Yamada T, Ishii T, Kumazawa S, Nakamura H, Masutani H, Yodoi J, Uchida K 2003 Thioredoxin as a molecular target of cyclopentenone prostaglandins. J Biol Chem 278:26046-26054
53. Moos PJ, Edes K, Cassidy P, Massuda E, Fitzpatrick FA 2003 Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 278:745-750
54. Shiota M, Yokomizo A, Naito S 2011 Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. Free Radic Biol Med 51:1320-1328
55. Surh YJ, Na HK, Park JM, Lee HN, Kim W, Yoon IS, Kim DD 2011 15-Deoxy-Δ(1)(2), (1)-prostaglandin J, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling. Biochem Pharmacol 82:1335-1351
56. Butler R, Mitchell SH, Tindall DJ, Young CY 2000 Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12, 14-prostaglandin J2. Cell Growth Differ 11:49-61
57. Chaffer CL, Thomas DM, Thompson EW, Williams ED 2006 PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6:53
58. Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K, Kohri K 2008 Peroxisome proliferator-activated receptor-γ and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev 32:259-266
59. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA 2003 Biosynthesis of 15-deoxy-Δ12, 14-PGJ2 and the ligation of PPARγ. J Clin Invest 112:945-955
60. Oh JY, Giles N, Landar A, Darley-Usmar V 2008 Accumulation of 15-deoxy-Δ(12, 14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defence induction. Biochem J 411:297-306